Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21

The 40-fold increase in childhood megakaryocyte-erythroid and B-cell leukemia in Down syndrome implicates trisomy 21 (T21) in perturbing fetal hematopoiesis. Here, we show that compared with primary disomic controls, primary T21 fetal liver (FL) hematopoietic stem cells (HSC) and megakaryocyte-erythroid progenitors are markedly increased, whereas granulocyte-macrophage progenitors are reduced. Commensurately, HSC and megakaryocyte-erythroid progenitors show higher clonogenicity, with increased megakaryocyte, megakaryocyte-erythroid, and replatable blast colonies. Biased megakaryocyte-erythroid–primed gene expression was detected as early as the HSC compartment. In lymphopoiesis, T21 FL lymphoid-primed multipotential progenitors and early lymphoid progenitor numbers are maintained, but there was a 10-fold reduction in committed PreproB-lymphoid progenitors and the functional B-cell potential of HSC and early lymphoid progenitor is severely impaired, in tandem with reduced early lymphoid gene expression. The same pattern was seen in all T21 FL samples and no samples had GATA1 mutations. Therefore, T21 itself causes multiple distinct defects in FL myelo- and lymphopoiesis.

[1]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[2]  J. Buckley,et al.  Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.

[3]  S. Orkin,et al.  miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. , 2010, Genes & development.

[4]  S. Orkin,et al.  Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. , 2010, Genes & development.

[5]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Verstegen,et al.  Down Syndrome B-Lymphocyte Subpopulations, Intrinsic Defect or Decreased T-Lymphocyte Help , 2010, Pediatric Research.

[7]  Elisa Laurenti,et al.  Hematopoiesis: a human perspective. , 2012, Cell stem cell.

[8]  P. Vyas,et al.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. , 2008, Blood.

[9]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[10]  Stylianos E. Antonarakis,et al.  Chromosome 21 and Down syndrome: from genomics to pathophysiology , 2004, Nature Reviews Genetics.

[11]  R. Reeves,et al.  Understanding the Basis for Down Syndrome Phenotypes , 2006, PLoS genetics.

[12]  G. Daley,et al.  Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells , 2011, Proceedings of the National Academy of Sciences.

[13]  M. Weiss,et al.  Trisomy 21 enhances human fetal erythro-megakaryocytic development. , 2008, Blood.

[14]  N. Heerema,et al.  Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. , 2005, Blood.

[15]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[16]  J. Birchler,et al.  Reflections on studies of gene expression in aneuploids. , 2010, The Biochemical journal.

[17]  Dario Greco,et al.  Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy , 2007, BMC Genomics.

[18]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[19]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[20]  A. F. Cunha,et al.  An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis , 2006, Nature Genetics.

[21]  M. Pletnikov,et al.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. , 2007, Human molecular genetics.

[22]  Harinder Singh,et al.  Contingent gene regulatory networks and B cell fate specification. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N. Hastie,et al.  Transcriptome analysis of human autosomal trisomy. , 2002, Human molecular genetics.

[24]  Jonathan Pevsner,et al.  Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. , 2003, Genomics.

[25]  R. Hardison,et al.  Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells , 2012, Proceedings of the National Academy of Sciences.

[26]  J. Crispino,et al.  Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. , 2012, The Journal of clinical investigation.

[27]  Shamit Soneji,et al.  Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. , 2007, Immunity.

[28]  P. Vyas,et al.  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. , 2011, Blood.

[29]  N. Sebire,et al.  ERG is a megakaryocytic oncogene. , 2009, Cancer research.

[30]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[31]  P. Vyas,et al.  Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML , 2008, Leukemia.

[32]  W. Pear,et al.  Notch signaling in mammalian hematopoietic stem cells , 2011, Leukemia.

[33]  R. Kirby,et al.  Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[34]  I. Weissman,et al.  Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. , 2007, Cell stem cell.

[35]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[36]  Jiangwen Zhang,et al.  Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. , 2009, Immunity.

[37]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[38]  Pedro Escoll,et al.  Ordering human CD34+CD10−CD19+ pre/pro-B-cell and CD19− common lymphoid progenitor stages in two pro-B-cell development pathways , 2010, Proceedings of the National Academy of Sciences.